Erlotinib in the treatment of advanced pancreatic cancer

Robin K Kelley, Andrew H KoUniversity of California, San Francisco, Comprehensive Cancer CenterAbstract: Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in combination have...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Robin K Kelley, Andrew H Ko
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b03fe3d41223428eac15921ce749ba74
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b03fe3d41223428eac15921ce749ba74
record_format	dspace
spelling	oai:doaj.org-article:b03fe3d41223428eac15921ce749ba742021-12-02T08:02:34ZErlotinib in the treatment of advanced pancreatic cancer1177-54751177-5491https://doaj.org/article/b03fe3d41223428eac15921ce749ba742008-03-01T00:00:00Zhttp://www.dovepress.com/erlotinib-in-the-treatment-of-advanced-pancreatic-cancer-a57https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Robin K Kelley, Andrew H KoUniversity of California, San Francisco, Comprehensive Cancer CenterAbstract: Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in combination have yielded disappointing results, spurring the ongoing search for new agents and combinations in this aggressive malignancy. Inhibitors of the epidermal growth factor receptor (EGFR) have shown promising activity in multiple solid tumors types, and preclinical data support a role for EGFR inhibition in pancreatic cancer. A recent phase III study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) demonstrated a significant survival benefit with the addition of the EGFR tyrosine kinase inhibitor, erlotinib to gemcitabine chemotherapy for the first-line treatment of patients with advanced pancreatic cancer, becoming the first phase III study to demonstrate a survival benefit of combination therapy as well as targeted therapy in this disease. This article reviews the evidence supporting EGFR inhibition and the use of erlotinib in advanced pancreatic cancer as well as future implications of targeted therapy in this challenging malignancy.Keywords: erlotinib, EGFR, pancreas, pancreatic, Tarceva Robin K KelleyAndrew H KoDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 1, Pp 83-95 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Robin K Kelley Andrew H Ko Erlotinib in the treatment of advanced pancreatic cancer
description	Robin K Kelley, Andrew H KoUniversity of California, San Francisco, Comprehensive Cancer CenterAbstract: Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in combination have yielded disappointing results, spurring the ongoing search for new agents and combinations in this aggressive malignancy. Inhibitors of the epidermal growth factor receptor (EGFR) have shown promising activity in multiple solid tumors types, and preclinical data support a role for EGFR inhibition in pancreatic cancer. A recent phase III study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) demonstrated a significant survival benefit with the addition of the EGFR tyrosine kinase inhibitor, erlotinib to gemcitabine chemotherapy for the first-line treatment of patients with advanced pancreatic cancer, becoming the first phase III study to demonstrate a survival benefit of combination therapy as well as targeted therapy in this disease. This article reviews the evidence supporting EGFR inhibition and the use of erlotinib in advanced pancreatic cancer as well as future implications of targeted therapy in this challenging malignancy.Keywords: erlotinib, EGFR, pancreas, pancreatic, Tarceva
format	article
author	Robin K Kelley Andrew H Ko
author_facet	Robin K Kelley Andrew H Ko
author_sort	Robin K Kelley
title	Erlotinib in the treatment of advanced pancreatic cancer
title_short	Erlotinib in the treatment of advanced pancreatic cancer
title_full	Erlotinib in the treatment of advanced pancreatic cancer
title_fullStr	Erlotinib in the treatment of advanced pancreatic cancer
title_full_unstemmed	Erlotinib in the treatment of advanced pancreatic cancer
title_sort	erlotinib in the treatment of advanced pancreatic cancer
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/b03fe3d41223428eac15921ce749ba74
work_keys_str_mv	AT robinkkelley erlotinibinthetreatmentofadvancedpancreaticcancer AT andrewhko erlotinibinthetreatmentofadvancedpancreaticcancer
_version_	1718398680448368640

Erlotinib in the treatment of advanced pancreatic cancer

Ejemplares similares